GL1X · GenesisL1 explorer

MolNFT v1 · #121610 · protein

Crystal structure of DR2231_E47A mutant in complex with dump

5I0J: “Crystal structure of DR2231_E47A mutant in complex with dump”. X-ray diffraction, 1 ligand (UMP), 7 pockets (best druggability 0.82). MolNFT v1 #121610 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
5I0J
Type
protein
Length
542 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
DR2231
UniProt
Q9RS96
Ligands
UMP
Pockets
7 · best druggability 0.82

Structure

x-ray diffraction · 4 distinct chains · 65% helix, 1% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ADR2231protein14062% helix, 1% strandQ9RS96
BDR2231protein13863% helix, 1% strandQ9RS96
CDR2231protein13267% helix, 0% strandQ9RS96
DDR2231protein13268% helix, 0% strandQ9RS96

Ligands and binding sites

  • UMP · 2'-deoxyuridine 5'-monophosphate · ligand · 2 copies · chains A, D, B, C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110780.820.83101UMP
21620.430.7425empty
3940.390.7720empty
4820.380.7719empty
5830.380.7717empty

Interfaces

6 interfaces between chains.

  • A–D · 3043 Ų buried · 16 hydrogen bonds · protein-protein
  • B–C · 3023 Ų buried · 21 hydrogen bonds · protein-protein
  • A–B · 201 Ų buried · 5 hydrogen bonds · protein-protein
  • B–D · 128 Ų buried · 1 hydrogen bond · protein-protein
  • A–C · 125 Ų buried · 1 hydrogen bond · protein-protein

Modifications

Observed in the structure: 1 disulfide (disulfide).

Compared structures

  • 5I0J · Crystal structure of DR2231_E47A mutant in complex with dUMP · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.